Abstract
Bortezomib has been licensed to be used in relapsed and refractory multiple myeloma. It is a promising agent for this incurable condition but our effort is to caution hematologists about the life-threatening neurotoxicity (grade 4) which was seen in two of six patients treated with this agent although the complication cannot definitely be attributed to bortezomib.
Vol. 91 No. 7 (2006): July, 2006 : Case Reports
Published By
Ferrata Storti Foundation, Pavia, Italy
Statistics from Altmetric.com
